A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS

My Portfolio

CLICK HERE to browse through descriptions of the implantable devices that I have developed

Important Disclaimer: The sole purpose of this page is to showcase the implantable device projects that I have led. The views presented in these pages do not necessarily reflect the views of my past or current employers, collaborators and/or clients. This information does not supersede original manufacturer’s specifications or constitute medical advice or advertisement. Trademarks and logos belong to their registered owners.

I have been developing implantable medical device systems since 1994.

Intermedics Logo

I was an engineer at Intermedics (Angleton, TX) between 1994 and 1998.  I was in charge of design and development of Intermedics’ next generation implantable cardiac pacemaker (NEXUS).  I defined the architecture and chipset for this next-generation implantable hardware platform, and specified and managed the development of fully custom analog, digital, mixed mode VLSI and MEMS integrated circuits.

At Intermedics I also did applied research, and developed protocols for assessing the hardness of implantable integrated electronics against therapeutic ionizing radiation. I also developed and tested novel technologies, circuits, sensors and methods applicable to implantable cardiac stimulators, along with analytical methods and instruments for in-vivo animal and human evaluation of new technologies (leads, implantable electrodes, cardiorespiratory and hemodynamic function sensors, therapies).

In 1998 I joined Prof. Shlomo Ben-Haim’s Impulse Dynamics to develop the company’s implantable devices for the treatment of heart failure. I developed the concept, core circuitry and control algorithms for all 5 generations of implantable cardiac contractility modulation (CCM) systems.

At Impulse Dynamics we discovered that the same type of non-excitatory signals used for cardiac contractility modulation could be used to control other excitable tissues.  MetaCure was spun-off Impulse Dynamics in 2008.  I was in charge of developing MetaCure’s two generations of platforms (Tantalus I for the treatment of obesity, Hyperion for the treatment of Diabetes, and Tantalus II for the treatment of metabolic syndrome).

CLICK HERE for my portfolio of other medical devices (including non-implantable and biomedical R&D) that I have designed.

CLICK HERE to browse through descriptions of the implantable devices that I have developed

You must be logged in to post a comment.